{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:35:19Z","timestamp":1649072119997},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00774-020-01111-3","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T04:02:46Z","timestamp":1589342566000},"page":"730-736","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer"],"prefix":"10.1007","volume":"38","author":[{"given":"Sung Hye","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Soo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"1111_CR1","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","volume":"32","author":"HJ Burstein","year":"2014","unstructured":"Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ (2014) Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: American Society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255","journal-title":"J Clin Oncol"},{"key":"1111_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Critic Rev Oncol\/Hematol 69:73\u201382","journal-title":"Critic Rev Oncol\/Hematol"},{"key":"1111_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.5114\/wo.2014.45305","volume":"19","author":"G Erbag","year":"2015","unstructured":"Erbag G, Uygun K, Binnetoglu E, Korkmaz AN, Asik M, Sen H, Gunes F, Eroglu M, Gokmen F, Temiz S (2015) Aromatase inhibitor treatment for breast cancer: short-term effect on bone health. Contemp Oncol (Poznan, Poland) 19:374\u2013377. https:\/\/doi.org\/10.5114\/wo.2014.45305","journal-title":"Contemp Oncol (Poznan, Poland)"},{"key":"1111_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.breast.2009.12.001","volume":"19","author":"SL Hines","year":"2010","unstructured":"Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL (2010) Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast (Edinburgh, Scotland) 19:92\u201396. https:\/\/doi.org\/10.1016\/j.breast.2009.12.001","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"1111_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000334456","volume":"81","author":"T Safra","year":"2011","unstructured":"Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB (2011) The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncol 81:298\u2013305. https:\/\/doi.org\/10.1159\/000334456","journal-title":"Oncol"},{"key":"1111_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-011-1728-3","volume":"130","author":"SA Lee","year":"2011","unstructured":"Lee SA, Hwang SH, Ahn SG, Lee HM, Jeong J, Lee HD (2011) Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients. Breast Can Res Treat 130:863\u2013887. https:\/\/doi.org\/10.1007\/s10549-011-1728-3","journal-title":"Breast Can Res Treat"},{"key":"1111_CR7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1200\/jco.2009.24.5902","volume":"28","author":"C Van Poznak","year":"2010","unstructured":"Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967\u2013975. https:\/\/doi.org\/10.1200\/jco.2009.24.5902","journal-title":"J Clin Oncol"},{"key":"1111_CR8","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00198-015-3100-7","volume":"26","author":"SL Greenspan","year":"2015","unstructured":"Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S (2015) Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporos Int 26:1857\u20131864. https:\/\/doi.org\/10.1007\/s00198-015-3100-7","journal-title":"Osteoporos Int"},{"key":"1111_CR9","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","volume":"14","author":"JE Lester","year":"2008","unstructured":"Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Can Res 14:6336\u20136342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5101","journal-title":"Clin Can Res"},{"key":"1111_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jbo.2012.06.002","volume":"1","author":"JE Lester","year":"2012","unstructured":"Lester JE, Dodwell D, Brown JE, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Coleman RE (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial. J Bone Oncol 1:57\u201362. https:\/\/doi.org\/10.1016\/j.jbo.2012.06.002","journal-title":"J Bone Oncol"},{"key":"1111_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1507\/endocrj.EJ12-0283","volume":"60","author":"Y Rhee","year":"2013","unstructured":"Rhee Y, Song K, Park S, Park HS, Lim SK, Park BW (2013) Efficacy of a combined alendronate and calcitriol agent (Maxmarvil(R)) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocrine J 60:167\u2013172","journal-title":"Endocrine J"},{"key":"1111_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jbo.2013.08.001","volume":"2","author":"AJ Lomax","year":"2013","unstructured":"Lomax AJ, Yee Yap S, White K, Beith J, Abdi E, Broad A, Sewak S, Lee C, Sambrook P, Pocock N, Henry MJ, Yeow EG, Bell R (2013) Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN Trial. J Bone Oncol 2:145\u2013153. https:\/\/doi.org\/10.1016\/j.jbo.2013.08.001","journal-title":"J Bone Oncol"},{"key":"1111_CR13","doi-asserted-by":"crossref","unstructured":"Pineda\u2010Moncus\u00ed M, Garcia\u2010Giralt N, Diez\u2010Perez A, Servitja S, Tusquets I, Prieto\u2010Alhambra D, Nogu\u00e9s X (2019) Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates. J Bone Miner Res","DOI":"10.1002\/jbmr.3886"},{"key":"1111_CR14","first-page":"252","volume":"100","author":"A Galvano","year":"2019","unstructured":"Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F (2019) Is there a role for denosumab and bone health for prostate and breast cancer patients undergoing endocrine therapy? A systematic review and a meta-analysis of randomized trials. J Bone Oncol 100:252","journal-title":"J Bone Oncol"},{"key":"1111_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nm.3961","volume":"21","author":"DL Waning","year":"2015","unstructured":"Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC et al (2015) Excess TGF-\u03b2 mediates muscle weakness associated with bone metastases in mice. Nat Med 21:1262\u20131271. https:\/\/doi.org\/10.1038\/nm.3961","journal-title":"Nat Med"},{"key":"1111_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ctrv.2009.12.010","volume":"36","author":"W Janni","year":"2010","unstructured":"Janni W, Hepp P (2010) Adjuvant aromatase inhibitor therapy: outcomes and safety. Can Treat Rev 36:249\u2013261","journal-title":"Can Treat Rev"},{"key":"1111_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/jcm2040283","volume":"2","author":"AH Paterson","year":"2013","unstructured":"Paterson AH, Shea-Budgell MA (2013) Bone health in patients with breast cancer: recommendations from an evidence-based Canadian guideline. J Clin Med 2:283\u2013301. https:\/\/doi.org\/10.3390\/jcm2040283","journal-title":"J Clin Med"},{"key":"1111_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000368843","volume":"9","author":"M Kalner","year":"2014","unstructured":"Kalner M, Hadji P (2014) Breast cancer and osteoporosis\u2014management of cancer treatment-induced bone loss in postmenopausal women with breast cancer. Breast Care (Basel, Switzerland) 9:312\u2013317. https:\/\/doi.org\/10.1159\/000368843","journal-title":"Breast Care (Basel, Switzerland)"},{"key":"1111_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10549-012-2023-7","volume":"133","author":"P Hadji","year":"2012","unstructured":"Hadji P, Hartenfels M, Kyvernitakis J, Hars O, Baumann KH, Kalder M (2012) Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL guideline evaluation study (MAGES). Breast Can Res Treat 133:1089\u20131096. https:\/\/doi.org\/10.1007\/s10549-012-2023-7","journal-title":"Breast Can Res Treat"},{"key":"1111_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/jco.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 1823323. J Clin Oncol 26:1051\u20131057. https:\/\/doi.org\/10.1200\/jco.2007.11.0726","journal-title":"J Clin Oncol"},{"key":"1111_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00198-016-3899-6","volume":"28","author":"A Hong","year":"2017","unstructured":"Hong A, Kim JH, Lee K-H, Kim T-Y, Im S-A, Moon H, Han W, Noh D, Kim S, Shin C (2017) Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 28:1413\u20131422","journal-title":"Osteoporos Int"},{"key":"1111_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jbmr.262","volume":"26","author":"S Khosla","year":"2011","unstructured":"Khosla S, Melton LJ III, Riggs BL (2011) The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 26:441\u2013451","journal-title":"J Bone Miner Res"},{"key":"1111_CR23","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1210\/jc.2009-2283","volume":"95","author":"FS Mirza","year":"2010","unstructured":"Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991\u20131997","journal-title":"J Clin Endocrinol Metab"},{"key":"1111_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jbmr.128","volume":"26","author":"UI M\u00f6dder","year":"2011","unstructured":"M\u00f6dder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S (2011) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26:27\u201334","journal-title":"J Bone Miner Res"},{"key":"1111_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.maturitas.2015.08.007","volume":"82","author":"S Morales-Santana","year":"2015","unstructured":"Morales-Santana S, D\u00edez-P\u00e9rez A, Olmos JM, Nogu\u00e9s X, Sosa M, D\u00edaz-Curiel M, P\u00e9rez-Castrill\u00f3n JL, P\u00e9rez-Cano R, Torrijos A, Jodar E (2015) Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis. Maturitas 82:402\u2013410","journal-title":"Maturitas"},{"key":"1111_CR26","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1056\/NEJM200106283442607","volume":"344","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997\u20132008. https:\/\/doi.org\/10.1056\/NEJM200106283442607","journal-title":"N Engl J Med"},{"key":"1111_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/02841860802001467","volume":"47","author":"NH Bjarnason","year":"2008","unstructured":"Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P (2008) Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol 47:747\u2013754. https:\/\/doi.org\/10.1080\/02841860802001467","journal-title":"Acta Oncol"},{"key":"1111_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.maturitas.2006.09.005","volume":"56","author":"P Hadji","year":"2007","unstructured":"Hadji P, Gottschalk M, Ziller V, Kalder M, Jackisch C, Wagner U (2007) Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT). Maturitas 56:312\u2013321","journal-title":"Maturitas"},{"key":"1111_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3803\/EnM.2015.30.1.58","volume":"30","author":"W Kim","year":"2015","unstructured":"Kim W, Chung Y, Kim SH, Park S, Bae JH, Kim G, Lee SJ, Kim JE, Park B-W, Lim S-K (2015) Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab 30:58\u201364","journal-title":"Endocrinol Metab"},{"key":"1111_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s40064-015-1096-2","volume":"4","author":"H Inoue","year":"2015","unstructured":"Inoue H, Hirano A, Ogura K, Hattori A, Kamimura M, Okubo F, Tagawa H, Sakaguchi S, Kinoshita J, Shimizu T (2015) The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer. SpringerPlus 4:303. https:\/\/doi.org\/10.1186\/s40064-015-1096-2","journal-title":"SpringerPlus"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01111-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01111-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01111-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T23:51:26Z","timestamp":1620863486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01111-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1111"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01111-3","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"16 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}